Obesity as an Additional Risk Factor for Thrombogenic Changes in Hemostasis in Hypertensive Patients with Non-Alcoholic Fatty Liver Disease

Abstract

Introduction: Obesity due to the high proportion of visceral adipose tissue is often leads to hypertension (HT), non-alcoholic fatty liver disease (NAFLD). The risk of thrombogenic complications increases in the presence of NAFLD and HT. Considering the occurrence of prothrombotic changes in the blood in patients with NAFLD, HT and obesity, the combination of these diseases may be an additional risk of thrombosis. Methods: The research was conducted at the Bogomolets National Medical University, at Department Propaedeutics of Internal Medicine No 1. We examined 152 patients and 15 individuals for control group. Results: Mean platelet count was higher in obese patients by 6.4% (p<0.05). In patients with NAFLD without HT, platelet count was higher in the presence of obesity by 16% (p<0.05), we have seen an increase level of MPV in NAFLD patients with obesity. In the comorbid course of HT and NAFLD, aggregation of platelets stimulated by adrenaline was grown in case of obesity (18%; p<0.001) relatively to non-obese patients. In obese patients suffering from HT, these hemostasis changes were characterized by a tendency to accelerate coagulation. There was a reduction in prothrombin time (PT) time by 8.1%, a growth in fibrinogen by 25.8% (p<0.001) and soluble fibrin monomeric complexes (SFMC) by 4 times (p<0.001) in obesity. Conclusion: Obesity increases the thrombogenic activity of blood in both patients with HT and in patients with HT and NAFLD, both due to platelet and coagulation of hemostasis.